Chargement en cours...
Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30(−) Tumors
Chimeric antigen receptor (CAR)-engineered T cells are efficacious in controlling advanced leukemia and lymphoma, however, they fail in the treatment of solid cancer, which is thought to be due to insufficient T cell activation. We revealed that the immune response of CAR T cells with specificity fo...
Enregistré dans:
| Publié dans: | Mol Ther |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society of Gene & Cell Therapy
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6822283/ https://ncbi.nlm.nih.gov/pubmed/31331813 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2019.06.007 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|